more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$159.69 USD

+0.16 (0.10%)

Updated Oct 8, 2024 04:00 PM ET

After-Market: $159.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5 4

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

by Zacks Equity Research Published on March 28,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe

by Zacks Equity Research Published on March 27,2017

Johnson & Johnson (JNJ) announced that the French health authority has granted approval to expand the label of Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes (MDS).

Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

by Zacks Equity Research Published on March 23,2017

We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

AT&T & Verizon Suspend Marketing Advertisements from YouTube

by Zacks Equity Research Published on March 23,2017

AT&T Inc. (T) and Verizon Communications Inc. (VZ) have decided to suspend their marketing campaign on Google's YouTube site.

5 Excellent ETFs for Your IRA

by Neena Mishra Published on March 20,2017

Low-cost, diversified ETFs are excellent investment vehicles to build retirement wealth.

Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

by Arpita Dutt Published on March 17,2017

Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China

by Zacks Equity Research Published on March 16,2017

Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz (5 mg taken twice daily) has received marketing approval in China to be used in combination with methotrexate

Large Cap ETF (IVV) Tops $100 billion in AUM

by Sweta Killa Published on March 10,2017

IVV is the second ETF in the space that has managed to garner $100 billion in AUM after SPY.

Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA

by Zacks Equity Research Published on March 09,2017

Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.

The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage

by Zacks Equity Research Published on March 07,2017

The Zacks Analyst Blog Highlights: Johnson & Johnson, Alphabet, Schlumberger, Alibaba and Public Storage

J&J Presents Positive Phase III Data on Psoriasis Candidate

by Zacks Equity Research Published on March 06,2017

Johnson & Johnson (JNJ) announced positive data from two phase III studies evaluating its pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis.

Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

by Zacks Equity Research Published on March 03,2017

Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat

by Zacks Equity Research Published on March 02,2017

Geron Corporation (GERN) reported a loss of 5 cents per share in the fourth quarter of 2016, flat year over year but narrower than the Zacks Consensus Estimate of a loss of 6 cents.

by Zacks Equity Research Published on February 28,2017

Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss

by Zacks Equity Research Published on February 27,2017

Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.

Dow 30 Stock Roundup: Wal-Mart, Home Depot Beat on Earnings, Boeing Wins $1.32B Order from Juneyao

by Swarup Gupta Published on February 24,2017

The Dow notched up a record streak of gains over a holiday shortened week.